SUBMIT BOOK PROPOSAL
Online Store
benthambooks logo

Site Breadcrumb

Nanocarrier-based Drug Delivery for the Management of Fatty Liver Disease

Editors: Anjali Sharma, Devkant Sharma, Ajmer Singh Grewal, Geeta Deswal, Ganga Reddy Velma

Nanocarrier-based Drug Delivery for the Management of Fatty Liver Disease

ISBN: 979-8-89881-568-4
eISBN: 979-8-89881-567-7 (Online)

Introduction

Nanocarrier-based Drug Delivery for the Management of Fatty Liver Disease is an advanced exploration of nanotechnology-driven therapeutic strategies for the diagnosis and treatment of fatty liver disease that is positioned at the intersection of nanomedicine, pharmacology, hepatology, and drug delivery.

The book begins with foundational concepts of fatty liver disease and its metabolic implications before introducing various nanocarrier-based drug delivery systems and liver-targeting strategies. Dedicated chapters discuss lipid-based nanocarriers, polymeric nanoparticles, dendrimers, and hybrid nanocarrier systems for therapeutic applications. It further explores novel therapeutics, nanocarrier-based imaging agents for diagnosis, pharmacokinetics and pharmacodynamics, and the safety and toxicity aspects of nanomedicine. Clinical translation, real-world case studies, and emerging trends in nanocarrier-assisted liver disease management are also comprehensively examined.


Key Features

  • - Comprehensive coverage of nanocarrier systems for fatty liver disease treatment.
  • - Discussions of lipid-based, polymeric, dendrimer, and hybrid nanocarriers.
  • - Insights into liver-targeted drug delivery and imaging technologies.
  • - Coverage of pharmacokinetics, toxicity, and clinical translation challenges.
  • - Focuses on emerging therapeutic strategies and future developments in nanomedicine.

Target Readership :

Researchers, clinicians, pharmacologists, scientists, postgraduate students, and academics in hepatology, pharmaceutical sciences, nanomedicine, drug delivery, and biomedical research.

Foreword

The field of nanomedicine has revolutionized modern therapeutics by enabling precise, targeted, and efficient delivery systems for drugs. Among the many diseases that demand innovative treatment strategies, Fatty Liver Disease (FLD)—both alcoholic and non-alcoholic—stands out as a global health challenge, affecting millions worldwide. The complexity of its pathophysiology necessitates advanced approaches that transcend conventional pharmacotherapy.

This book, “Nanocarrier-based Drug Delivery for the Management of Fatty Liver Disease,” provides a comprehensive and insightful exploration of the potential of nanotechnology to address this pressing medical concern. From the fundamentals of fatty liver disease to sophisticated nanocarrier-based therapeutic and diagnostic approaches, the book integrates scientific innovation with clinical relevance.

Each chapter, authored by distinguished experts in the field, delves into critical aspects such as liver-targeting nanocarriers, lipid- and polymer-based systems, pharmacokinetic considerations, safety profiles, and translational perspectives. This book is expected to serve as a valuable resource for researchers, academicians, clinicians, and pharmaceutical scientists seeking to leverage nanotechnology for the management of liver diseases. It is a commendable initiative that bridges the gap between nanoscience and hepatology, paving the way for future advancements in precision medicine.

I extend my heartfelt congratulations to the authors for their dedicated efforts in bringing this comprehensive and insightful book to fruition.

Bhawna Chopra
Guru Gobind Singh College of Pharmacy, Yamuna Nagar
Haryana, India